loading
전일 마감가:
$117.88
열려 있는:
$117.12
하루 거래량:
271.44K
Relative Volume:
0.04
시가총액:
$147.41B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
23.64
EPS:
5.0273
순현금흐름:
$9.37B
1주 성능:
-2.21%
1개월 성능:
+5.47%
6개월 성능:
+13.98%
1년 성능:
+34.85%
1일 변동 폭
Value
$116.70
$118.96
1주일 범위
Value
$116.70
$121.88
52주 변동 폭
Value
$86.08
$124.61

길리어드 사이언스 Stock (GILD) Company Profile

Name
명칭
Gilead Sciences Inc
Name
전화
(650) 574-3000
Name
주소
333 LAKESIDE DR, FOSTER CITY, CA
Name
직원
17,600
Name
트위터
@GileadSciences
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
GILD's Discussions on Twitter

GILD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
118.80 146.27B 28.80B 6.31B 9.37B 5.0273
Drug Manufacturers - General icon
LLY
Lilly Eli Co
820.19 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.11 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.15 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.69 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.65 217.38B 63.43B 16.42B 14.72B 6.4861

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-19 업그레이드 Daiwa Securities Neutral → Outperform
2025-08-08 업그레이드 Truist Hold → Buy
2025-07-25 업그레이드 Needham Hold → Buy
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-03-04 재확인 Oppenheimer Outperform
2025-02-18 업그레이드 Deutsche Bank Hold → Buy
2025-02-13 업그레이드 DZ Bank Hold → Buy
2025-01-10 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-12-10 재개 BofA Securities Buy
2024-11-15 개시 Wolfe Research Outperform
2024-11-14 개시 Citigroup Buy
2024-11-08 다운그레이드 Maxim Group Buy → Hold
2024-10-21 업그레이드 Leerink Partners Market Perform → Outperform
2024-10-17 개시 Bernstein Outperform
2024-10-07 업그레이드 Wells Fargo Equal Weight → Overweight
2024-07-08 업그레이드 Raymond James Mkt Perform → Outperform
2024-05-01 재확인 Maxim Group Buy
2024-04-24 업그레이드 HSBC Securities Reduce → Hold
2024-02-22 다운그레이드 Truist Buy → Hold
2023-11-09 개시 Deutsche Bank Hold
2023-09-08 업그레이드 BofA Securities Neutral → Buy
2023-09-06 개시 HSBC Securities Reduce
2023-07-24 재확인 Barclays Equal Weight
2023-05-16 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-04-28 재개 Piper Sandler Overweight
2023-01-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2022-12-13 재개 BofA Securities Neutral
2022-12-09 다운그레이드 DZ Bank Buy → Hold
2022-10-31 업그레이드 Barclays Underweight → Equal Weight
2022-10-28 재확인 BMO Capital Markets Market Perform
2022-10-28 재확인 Cowen Outperform
2022-10-28 재확인 JP Morgan Overweight
2022-10-28 재확인 Jefferies Buy
2022-10-28 업그레이드 Piper Sandler Neutral → Overweight
2022-10-28 재확인 RBC Capital Mkts Outperform
2022-10-28 업그레이드 Truist Hold → Buy
2022-10-28 재확인 Wells Fargo Equal Weight
2022-10-04 업그레이드 JP Morgan Neutral → Overweight
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-05-23 개시 SVB Leerink Mkt Perform
2022-02-28 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-02-02 재확인 BMO Capital Markets Outperform
2022-02-02 재확인 BofA Securities Neutral
2022-02-02 재확인 RBC Capital Mkts Outperform
2022-02-02 재확인 Truist Hold
2022-02-02 재확인 Wells Fargo Equal Weight
2022-01-28 업그레이드 Argus Hold → Buy
2022-01-06 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-12-09 재개 Wells Fargo Equal Weight
2021-12-06 개시 Goldman Neutral
2021-11-19 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-11-19 재개 Piper Sandler Neutral
2021-10-20 재개 Cowen Outperform
2021-07-30 재확인 BMO Capital Markets Market Perform
2021-07-30 재확인 RBC Capital Mkts Outperform
2021-04-01 업그레이드 Bernstein Mkt Perform → Outperform
2021-03-30 업그레이드 Redburn Neutral → Buy
2021-01-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-11-03 재개 Morgan Stanley Equal-Weight
2020-10-28 개시 UBS Neutral
2020-09-30 재개 Jefferies Buy
2020-09-15 업그레이드 Maxim Group Hold → Buy
2020-07-31 재확인 Credit Suisse Neutral
2020-07-31 재확인 Morgan Stanley Equal-Weight
2020-07-31 재확인 Piper Sandler Overweight
2020-07-31 재확인 RBC Capital Mkts Outperform
2020-07-31 재확인 SunTrust Hold
2020-07-31 재확인 Wells Fargo Equal Weight
2020-07-20 업그레이드 Credit Suisse Underperform → Neutral
2020-06-03 업그레이드 SVB Leerink Mkt Perform → Outperform
2020-05-26 업그레이드 SunTrust Sell → Hold
2020-05-01 다운그레이드 JP Morgan Overweight → Neutral
2020-05-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-05-01 다운그레이드 SunTrust Hold → Sell
2020-04-27 다운그레이드 UBS Buy → Neutral
2020-04-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2020-04-20 다운그레이드 Wells Fargo Overweight → Equal Weight
2020-04-17 다운그레이드 CFRA Hold → Sell
모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

pulisher
Oct 28, 2025

Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings - The Globe and Mail

Oct 28, 2025
pulisher
Oct 28, 2025

Income Plays: Is Gilead Sciences Inc. stock attractive for long term wealth buildingCEO Change & Smart Investment Allocation Insights - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Weekly Trades: How Gilead Sciences Inc. stock performs in rate cut cycles2025 Geopolitical Influence & Verified Short-Term Plans - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

AmBisome Market 2025 Is Booming Worldwide by 2032 |Gilead Sciences Inc and Astellas Pharma Inc - openPR.com

Oct 28, 2025
pulisher
Oct 28, 2025

Using data tools to time your Gilead Sciences Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Gilead Sciences Inc. stock cheap at current valuation2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Gilead Sciences Inc. (GIS) stock sustain dividend payoutsJuly 2025 Rallies & Community Trade Idea Sharing Platform - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

François Cherifi: Deeply Grateful to Gilead Sciences for Awarding me the Gilead Scholarship at ESMO2025 - Oncodaily

Oct 28, 2025
pulisher
Oct 27, 2025

Will Gilead Sciences Inc. stock remain a Wall Street favorite2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Exit strategy if you’re trapped in Gilead Sciences Inc.July 2025 Gainers & Growth Focused Entry Reports - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is this a good reentry point in Gilead Sciences Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Using economic indicators to assess Gilead Sciences Inc. potentialJuly 2025 Earnings & Reliable Trade Execution Plans - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Gilead Sciences Inc. stock attractive for long term wealth buildingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Gilead Sciences’ GS-1219 HIV Study Update: Implications for Investors - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Gilead Sciences: Strong Market Position and Growth Potential in HIV and PrEP with Promising Yeztugo Launch - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Will Gilead Sciences Inc. stock sustain high P E ratiosJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitMarket Rally & High Accuracy Trade Signal Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Gilead Sciences VP Praises China's Reforms for Helping Launch More Novel Drugs - Yicai Global

Oct 27, 2025
pulisher
Oct 27, 2025

Will Gilead Sciences Inc. outperform the marketEarnings Growth Report & Expert Verified Movement Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Gilead Sciences Inc. still worth holding after the dip2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a buy for dividend portfolios2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsPortfolio Risk Summary & Real-Time Market Trend Scan - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

How to build a dashboard for Gilead Sciences Inc. stockShare Buyback & Daily Profit Focused Screening - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Is Gilead Sciences Inc. (GIS) stock inflation resilientEarnings Summary Report & Verified High Yield Trade Plans - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Gilead Sciences Experiences Valuation Adjustment Amid Strong Market Performance and Metrics - Markets Mojo

Oct 26, 2025
pulisher
Oct 25, 2025

Florida Settlement with Gilead Sciences for Improper Promotion of HIV Drugs - West Orlando News

Oct 25, 2025
pulisher
Oct 25, 2025

Chart based exit strategy for Gilead Sciences Inc.Market Performance Summary & AI Forecasted Entry and Exit Points - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

Gilead Sciences Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com

Oct 25, 2025
pulisher
Oct 24, 2025

Morgan Stanley Remains Bullish on Gilead Sciences (GILD) - MSN

Oct 24, 2025
pulisher
Oct 24, 2025

What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha

Oct 24, 2025
pulisher
Oct 24, 2025

Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech

Oct 24, 2025
pulisher
Oct 24, 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace

Oct 24, 2025
pulisher
Oct 23, 2025

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com

Oct 23, 2025
pulisher
Oct 23, 2025

TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 - GuruFocus

Oct 23, 2025
pulisher
Oct 23, 2025

Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com

Oct 23, 2025

길리어드 사이언스 (GILD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

길리어드 사이언스 주식 (GILD) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Dickinson Andrew D
Chief Financial Officer
Oct 15 '25
Sale
118.08
2,500
295,200
157,055
Mercier Johanna
Chief Commercial Officer
Oct 15 '25
Sale
118.08
3,000
354,240
110,193
drug_manufacturers_general PFE
$24.52
price up icon 0.08%
$292.08
price down icon 0.16%
drug_manufacturers_general SNY
$51.44
price up icon 0.76%
drug_manufacturers_general NVO
$52.42
price up icon 0.65%
drug_manufacturers_general MRK
$87.50
price up icon 0.52%
자본화:     |  볼륨(24시간):